Novo Nordisk's Wegovy Approved for Liver Disease, Ozempic Price Cut

FDA Approval for MASH

• 🎯 Wegovy, Novo Nordisk's weight loss drug, has received FDA approval to treat MASH (metabolic dysfunction-associated steatohepatitis), a serious liver condition.
• 💡 This approval expands the use of GLP-1 drugs beyond obesity, aiming to secure broader insurance coverage.
• 📈 Analysts estimate the MASH indication could add nearly $2 billion in peak sales for Novo Nordisk.
• 🔬 Novo Nordisk executives state Wegovy treats the underlying metabolic drivers of MASH, reinforcing its efficacy beyond weight loss.

Pricing and Accessibility

• 💰 Novo Nordisk announced that its diabetes drug, Ozempic, will be available for $4.99 per month for out-of-pocket payers, a significant reduction from its usual $1,000 monthly cost.
• 🛒 This pricing initiative mirrors the availability of Wegovy on Novo Nordisk's direct-to-consumer platform, Novocare.
• 🔑 Both Ozempic and Wegovy share the same active ingredient, with dosage being the primary differentiator, and will now have the same out-of-pocket monthly price.

Market Strategy and Competition

• 🌐 While Ozempic has high insurance coverage for diabetes (around 98%), Novo Nordisk aims to increase awareness and accessibility for both drugs, potentially attracting users who might otherwise opt for compounded versions.
• ⚔️ The move is seen as a strategy to compete with companies selling knockoff versions of GLP-1 drugs at lower prices.